These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17424926)

  • 1. [Rimonabant--a panacea for patients with metabolic syndrome?].
    Broncel M; Koziróg M
    Pol Arch Med Wewn; 2006 Aug; 116(2):787-93. PubMed ID: 17424926
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
    MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.
    O'Leary DH; Reuwer AQ; Nissen SE; Després JP; Deanfield JE; Brown MW; Zhou R; Zabbatino SM; Job B; Kastelein JJ; Visseren FL;
    Heart; 2011 Jul; 97(14):1143-50. PubMed ID: 21610270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
    Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
    Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selective cannabinoid receptor antagonists].
    Kreutz S; Korf HW; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
    Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
    Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.
    Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC
    Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063
    [No Abstract]   [Full Text] [Related]  

  • 12. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 13. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 14. [Endocannabinoids receptor blocker lets tumble not only money. A drug against metabolic syndrome?].
    Aumiller J
    MMW Fortschr Med; 2004 Nov; 146(45):12. PubMed ID: 15581096
    [No Abstract]   [Full Text] [Related]  

  • 15. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
    Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
    Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
    Després JP; Ross R; Boka G; Alméras N; Lemieux I;
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention.
    Ahmed MH
    Saudi Med J; 2007 May; 28(5):806-8. PubMed ID: 17457461
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel therapies for cardiometabolic risk reduction and implications for clinical practice.
    Watson KE
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S37-42. PubMed ID: 17934393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
    Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
    Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.